Inovio Pharmaceuticals shares are trading higher after the company announced it received FDA feedback that the data from the completed Phase 1/2 trial of INO-3107 can be used to submit a BLA under the FDA's accelerated approval program.
Portfolio Pulse from Benzinga Newsdesk
Inovio Pharmaceuticals has received FDA feedback that data from the completed Phase 1/2 trial of INO-3107 can be used to submit a Biologics License Application (BLA) under the FDA's accelerated approval program. This news has led to a rise in the company's share prices.
October 10, 2023 | 6:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inovio Pharmaceuticals' stock is trading higher following FDA feedback that allows for an accelerated approval program submission using Phase 1/2 trial data of INO-3107.
The FDA's feedback is a positive development for Inovio Pharmaceuticals, as it allows the company to submit a BLA under the FDA's accelerated approval program. This news is likely to boost investor confidence in the company, leading to a rise in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100